102 related articles for article (PubMed ID: 19407573)
1. Attitudes regarding the use of hematopoietic colony-stimulating factors and maintenance of relative dose intensity among gynecologic oncologists.
Alvarez Secord A; Bae-Jump V; Havrilesky LJ; Calingaert B; Clarke-Pearson DL; Soper JT; Gehrig PA
Int J Gynecol Cancer; 2009 Apr; 19(3):447-54. PubMed ID: 19407573
[TBL] [Abstract][Full Text] [Related]
2. Use of hematopoietic colony-stimulating factors: the American Society of Clinical Oncology survey. The Health Services Research Committee of the American Society of Clinical Oncology.
Bennett CL; Smith TJ; Weeks JC; Bredt AB; Feinglass J; Fetting JH; Hillner BE; Somerfield MR; Winn RJ
J Clin Oncol; 1996 Sep; 14(9):2511-20. PubMed ID: 8823330
[TBL] [Abstract][Full Text] [Related]
3. Use of hematopoietic colony-stimulating factors: comparison of the 1994 and 1997 American Society of Clinical Oncology surveys regarding ASCO clinical practice guidelines. Health Services Research Committee of the American Society of Clinical Oncology.
Bennett CL; Weeks JA; Somerfield MR; Feinglass J; Smith TJ
J Clin Oncol; 1999 Nov; 17(11):3676-81. PubMed ID: 10550166
[TBL] [Abstract][Full Text] [Related]
4. American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines.
J Clin Oncol; 1994 Nov; 12(11):2471-508. PubMed ID: 7964965
[TBL] [Abstract][Full Text] [Related]
5. Growth factor usage patterns and outcomes in the community setting: collection through a practice-based computerized clinical information system.
Swanson G; Bergstrom K; Stump E; Miyahara T; Herfindal ET
J Clin Oncol; 2000 Apr; 18(8):1764-70. PubMed ID: 10764438
[TBL] [Abstract][Full Text] [Related]
6. Colony-stimulating factors for the management of neutropenia in cancer patients.
Dale DC
Drugs; 2002; 62 Suppl 1():1-15. PubMed ID: 12479591
[TBL] [Abstract][Full Text] [Related]
7. Attitudes and practice patterns for maintaining relative dose intensity of chemotherapy in outpatient clinics: results of a Japanese web-based survey.
Sakai H; Katsumata N; Kadokura G
BMC Cancer; 2015 Oct; 15():651. PubMed ID: 26438185
[TBL] [Abstract][Full Text] [Related]
8. Practice Patterns, Attitudes, and Barriers to Palliative Care Consultation by Gynecologic Oncologists.
Buckley de Meritens A; Margolis B; Blinderman C; Prigerson HG; Maciejewski PK; Shen MJ; Hou JY; Burke WM; Wright JD; Tergas AI
J Oncol Pract; 2017 Sep; 13(9):e703-e711. PubMed ID: 28783424
[TBL] [Abstract][Full Text] [Related]
9. Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study.
Tan H; Tomic K; Hurley D; Daniel G; Barron R; Malin J
Curr Med Res Opin; 2011 Jan; 27(1):79-86. PubMed ID: 21091127
[TBL] [Abstract][Full Text] [Related]
10. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices.
Lyman GH; Dale DC; Crawford J
J Clin Oncol; 2003 Dec; 21(24):4524-31. PubMed ID: 14673039
[TBL] [Abstract][Full Text] [Related]
11. Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy.
Shayne M; Culakova E; Poniewierski MS; Wolff D; Dale DC; Crawford J; Lyman GH
Cancer; 2007 Oct; 110(7):1611-20. PubMed ID: 17705197
[TBL] [Abstract][Full Text] [Related]
12. A survey of the practice patterns of gynecologic oncologists dealing with hereditary cancer patients in Japan.
Tanabe N; Shikama A; Bando H; Satoh T; Shimizu C
Fam Cancer; 2014 Sep; 13(3):489-98. PubMed ID: 24853694
[TBL] [Abstract][Full Text] [Related]
13. Use of granulocyte colony-stimulating factor: a survey among Italian medical oncologists.
Danova M; Rosti G; De Placido S; Bencardino K; Venturini M
Oncol Rep; 2005 Dec; 14(6):1405-12. PubMed ID: 16273232
[TBL] [Abstract][Full Text] [Related]
14. How did the Introduction of Biosimilar Filgrastim Influence the Prescribing Pattern of Granulocyte Colony-Stimulating Factors? Results from a Multicentre, Population-Based Study, from Five Italian Centres in the Years 2009-2014.
Marcianò I; Ingrasciotta Y; Giorgianni F; Bolcato J; Chinellato A; Pirolo R; Di Giorgio A; Manna S; Ientile V; Gini R; Santarpia M; Genazzani AA; Uomo I; Pastorello M; Pollina Addario SW; Scondotto S; Cananzi P; Da Cas R; Traversa G; Rossi M; Sottosanti L; Caputi AP; Trifirò G
BioDrugs; 2016 Aug; 30(4):295-306. PubMed ID: 27138636
[TBL] [Abstract][Full Text] [Related]
15. Gynecologic cancer survivor preferences for long-term surveillance.
Schlumbrecht M; Sun C; Huang M; Milbourne A; Bodurka D
BMC Cancer; 2018 Apr; 18(1):375. PubMed ID: 29614979
[TBL] [Abstract][Full Text] [Related]
16. A nationwide survey of oncologists regarding treatment-related infertility and fertility preservation in female cancer patients.
Forman EJ; Anders CK; Behera MA
Fertil Steril; 2010 Oct; 94(5):1652-6. PubMed ID: 19945099
[TBL] [Abstract][Full Text] [Related]
17. Use of granulocyte colony-stimulating factor (G-CSF) in patients receiving myelosuppressive chemotherapy for the treatment of cancer. Provincial Systemic Treatment Disease Site Group.
Rusthoven J; Bramwell V; Stephenson B
Cancer Prev Control; 1998 Aug; 2(4):179-90. PubMed ID: 10093631
[TBL] [Abstract][Full Text] [Related]
18. Improving the relative dose intensity of systemic chemotherapy in a community-based outpatient cancer center.
Vavra KL; Saadeh CE; Rosen AL; Uptigrove CE; Srkalovic G
J Oncol Pract; 2013 Sep; 9(5):e203-11. PubMed ID: 23943886
[TBL] [Abstract][Full Text] [Related]
19. Factors influencing fertility-sparing treatment for gynecologic malignancies: A survey of Society of Gynecologic Oncology members.
Shah JS; Guerra R; Bodurka DC; Sun CC; Chisholm GB; Woodard TL
Gynecol Oncol; 2017 Dec; 147(3):497-502. PubMed ID: 28941656
[TBL] [Abstract][Full Text] [Related]
20. The role of colony-stimulating factors and granulocyte transfusion in treatment options for neutropenia in children with cancer.
Liang DC
Paediatr Drugs; 2003; 5(10):673-84. PubMed ID: 14510625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
